SkinBioTherapeutics Statistics

Total Valuation

SkinBioTherapeutics has a market cap or net worth of GBP 39.98 million. The enterprise value is 39.99 million.

Market Cap	39.98M
Enterprise Value	39.99M

Important Dates

The next estimated earnings date is Friday, March 21, 2025.

Earnings Date	Mar 21, 2025
Ex-Dividend Date	n/a

Share Statistics

SkinBioTherapeutics has 228.44 million shares outstanding. The number of shares has increased by 13.10% in one year.

Current Share Class	n/a
Shares Outstanding	228.44M
Shares Change (YoY)	+13.10%
Shares Change (QoQ)	+10.63%
Owned by Insiders (%)	4.62%
Owned by Institutions (%)	47.07%
Float	172.13M

Valuation Ratios

PE Ratio	n/a
Forward PE	n/a
PS Ratio	26.97
PB Ratio	11.92
P/TBV Ratio	n/a
P/FCF Ratio	n/a
P/OCF Ratio	n/a
PEG Ratio	n/a

Financial Ratio History

Enterprise Valuation

EV / Earnings	-13.91
EV / Sales	33.09
EV / EBITDA	n/a
EV / EBIT	n/a
EV / FCF	-14.59

Financial Position

The company has a current ratio of 0.93, with a Debt / Equity ratio of 0.28.

Current Ratio	0.93
Quick Ratio	0.63
Debt / Equity	0.28
Debt / EBITDA	n/a
Debt / FCF	-0.30
Interest Coverage	-66.39

Financial Efficiency

Return on equity (ROE) is -115.86% and return on invested capital (ROIC) is -61.71%.

Return on Equity (ROE)	-115.86%
Return on Assets (ROA)	-46.50%
Return on Capital (ROIC)	-61.71%
Revenue Per Employee	80,578
Profits Per Employee	-191,733
Employee Count	15
Asset Turnover	0.31
Inventory Turnover	2.08

Taxes

Income Tax	n/a
Effective Tax Rate	n/a

Stock Price Statistics

The stock price has increased by +6.67% in the last 52 weeks. The beta is 1.77, so SkinBioTherapeutics's price volatility has been higher than the market average.

Beta (5Y)	1.77
52-Week Price Change	+6.67%
50-Day Moving Average	16.50
200-Day Moving Average	12.52
Relative Strength Index (RSI)	56.82
Average Volume (20 Days)	507,895

Short Selling Information

Short Interest	n/a
Short Previous Month	n/a
Short % of Shares Out	n/a
Short % of Float	n/a
Short Ratio (days to cover)	n/a

Income Statement

In the last 12 months, SkinBioTherapeutics had revenue of GBP 1.21 million and -2.88 million in losses. Loss per share was -0.02.

Revenue	1.21M
Gross Profit	683,038
Operating Income	-2.91M
Pretax Income	-2.95M
Net Income	-2.88M
EBITDA	-2.77M
EBIT	-2.91M
Loss Per Share	-0.02

Full Income Statement

Balance Sheet

The company has 800,904 in cash and 818,742 in debt, giving a net cash position of -17,838 or -0.00 per share.

Cash & Cash Equivalents	800,904
Total Debt	818,742
Net Cash	-17,838
Net Cash Per Share	-0.00
Equity (Book Value)	2.97M
Book Value Per Share	0.01
Working Capital	-133,287

Full Balance Sheet

Cash Flow

In the last 12 months, operating cash flow was -2.73 million and capital expenditures -14,959, giving a free cash flow of -2.74 million.

Operating Cash Flow	-2.73M
Capital Expenditures	-14,959
Free Cash Flow	-2.74M
FCF Per Share	-0.01

Full Cash Flow Statement

Margins

Gross margin is 56.51%, with operating and profit margins of -240.36% and -237.95%.

Gross Margin	56.51%
Operating Margin	-240.36%
Pretax Margin	-243.98%
Profit Margin	-237.95%
EBITDA Margin	-229.38%
EBIT Margin	-240.36%
FCF Margin	n/a

Dividends & Yields

SkinBioTherapeutics does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	n/a
Buyback Yield	-13.10%
Shareholder Yield	-13.10%
Earnings Yield	n/a
FCF Yield	n/a

Stock Splits

This stock does not have any record of stock splits.

Last Split Date	n/a
Split Type	n/a
Split Ratio	n/a

Scores

SkinBioTherapeutics has an Altman Z-Score of 1.92. A Z-score under 3 suggests an increased risk of bankruptcy.

Altman Z-Score	1.92
Piotroski F-Score	n/a